Your session is about to expire
← Back to Search
Radiation Therapy
Advanced Imaging & Software for Head and Neck Cancer
N/A
Recruiting
Research Sponsored by Varian, a Siemens Healthineers Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 4 weeks
Awards & highlights
Study Summary
This trial looks at using advanced imaging & software to plan the best treatment for head & neck cancer.
Who is the study for?
This trial is for adults over 19 with head and neck cancer who are set to receive radiation therapy at the NS Health QE2 site. They must be scheduled for a minimum of 21 treatment sessions. Pregnant individuals, those not consenting, or patients with prior treatments like bilateral neck dissection/laryngectomy or radiation to oral cavity/sinuses cannot participate.Check my eligibility
What is being tested?
The study is testing the effectiveness of HyperSight CBCT imaging combined with adaptive planning software in creating real-time and adjusted radiotherapy plans for treating head and neck cancers.See study design
What are the potential side effects?
As this trial focuses on imaging technology rather than medication, side effects may not be as common as drug trials. However, there could be risks associated with additional exposure to radiation from frequent imaging.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 4 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~4 weeks
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Evaluate potential reduction in time and resources required for offline plan adaptation
Evaluation of CBCT-based dosimetry calculations
Improvements in radiation dosimetry from using online adaptation
+1 moreSecondary outcome measures
CBCT image quality
Patient experience questionnaire
Trial Design
1Treatment groups
Experimental Treatment
Group I: HyperSight Imaging ArmExperimental Treatment1 Intervention
Subjects imaged with the new HyperSight CBCT imaging system.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
CBCT Imaging
2022
N/A
~30
Find a Location
Who is running the clinical trial?
Varian, a Siemens Healthineers CompanyLead Sponsor
30 Previous Clinical Trials
7,243 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am undergoing radiation therapy for head or neck cancer with at least 21 treatments.I am not willing or able to give consent to participate in the study.I have had radiation therapy to my mouth or sinuses.I have had surgery to remove lymph nodes in my neck or my voice box.I am 19 years old or older.
Research Study Groups:
This trial has the following groups:- Group 1: HyperSight Imaging Arm
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Are there any opportunities currently available for prospective participants?
"Clinicaltrials.gov confirms that enrollment for this medical trial is currently suspended, having been initially posted on March 1st 2023 and last updated December 16th 2022. However, 476 other trials are actively searching for participants at the present moment."
Answered by AI
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger